Published in Ann Surg on March 01, 2016
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med (2014) 10.69
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol (2001) 10.20
Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg (1992) 9.97
Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst (2006) 7.29
Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer (2006) 3.86
Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol (1999) 3.74
Pathologic examination of the sentinel lymph node in malignant melanoma. Am J Surg Pathol (1999) 1.68
Reliability of identification of 655 sentinel lymph nodes in 263 consecutive patients with malignant melanoma. J Am Coll Surg (2004) 1.55
Comparing the hybrid fluorescent-radioactive tracer indocyanine green-99mTc-nanocolloid with 99mTc-nanocolloid for sentinel node identification: a validation study using lymphoscintigraphy and SPECT/CT. J Nucl Med (2012) 1.53
Clinical significance of occult metastatic melanoma in sentinel lymph nodes and other high-risk factors based on long-term follow-up. World J Surg (2005) 1.47
Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer (2003) 1.38
Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: review of a large single-institutional experience with an emphasis on recurrence. Ann Surg (2001) 1.36
Adverse reactions to isosulfan blue during selective sentinel lymph node dissection in melanoma. Ann Surg Oncol (2000) 1.28
Localizing the sentinel node in cutaneous melanoma: gamma probe detection versus blue dye. Ann Surg Oncol (1997) 1.13
Regional recurrence after negative sentinel lymph node biopsy for melanoma. Ann Surg (2008) 1.12
Combined analysis of phase III trials evaluating [⁹⁹mTc]tilmanocept and vital blue dye for identification of sentinel lymph nodes in clinically node-negative cutaneous melanoma. Ann Surg Oncol (2012) 1.11
Anaphylactic response to blue dye during sentinel lymph node biopsy. Surg Oncol (2010) 1.10
Factors associated with false-negative sentinel lymph node biopsy in melanoma patients. Ann Surg Oncol (2009) 1.08
Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid. Surgery (1998) 1.02
Effective low-dose escalation of indocyanine green for near-infrared fluorescent sentinel lymph node mapping in melanoma. Ann Surg Oncol (2013) 1.00
Sentinel lymph node biopsy in patients with primary cutaneous melanoma: study of 455 cases. J Eur Acad Dermatol Venereol (2000) 0.96
Intraoperative imaging guidance for sentinel node biopsy in melanoma using a mobile gamma camera. Ann Surg (2011) 0.94
Accuracy of pathologic techniques for the diagnosis of metastatic melanoma in sentinel lymph nodes. Ann Surg Oncol (1999) 0.93
Sentinel lymph node biopsy performed with local anesthesia in patients with early-stage breast carcinoma. Arch Surg (2002) 0.90
The use of radioisotope combined with isosulfan Blue dye is not superior to radioisotope alone for the identification of sentinel lymph nodes in patients with breast cancer. Surgery (2008) 0.87
Sentinel node localization in cutaneous melanoma: lymphoscintigraphy with colloids and antibody fragments versus blue dye mapping. Eur J Nucl Med (1998) 0.86
Indocyanine green and fluorescence lymphangiography for sentinel lymph node identification in cutaneous melanoma. J Surg Oncol (2014) 0.85
Selective sentinel lymph node dissection for melanoma: importance of harvesting nodes with lower radioactive counts without the need for blue dye. Ann Surg Oncol (2011) 0.83
Gamma probe guided biopsy of the sentinel node in malignant melanoma: a multicentre study. Melanoma Res (2001) 0.82
Outcome of sentinel lymph node biopsy and prognostic implications of regression in thin malignant melanoma. Melanoma Res (2012) 0.82
What is a sentinel node? Re-evaluating the 10% rule for sentinel lymph node biopsy in melanoma. J Surg Oncol (2007) 0.80
Sentinel lymph node biopsy in patients with Stage I/II melanoma: Clinical experience and literature review. J Surg Oncol (2004) 0.80
Sentinel lymph node biopsy under local anaesthesia versus general anaesthesia: reliability and cost-effectiveness analysis in 153 patients with malignant melanoma. In Vivo (2012) 0.79
[Intraoperative detection of sentinel lymph nodes in cutaneous malignant melanoma -- blue dye alone versus blue dye plus gamma detection]. J Dtsch Dermatol Ges (2005) 0.78
Mapping the sentinel lymph node in malignant melanoma by blue dye, lymphoscintigraphy and intraoperative gamma probe. Tumori (2000) 0.77
Incidence of adverse reactions to patent blue dye in melanoma sentinel node biopsy: a major UK centre experience. J Plast Reconstr Aesthet Surg (2013) 0.77
[Sentinel lymph node identification in the staging of cutaneous melanoma. Blue dye vs. radioguided localization]. Minerva Chir (2001) 0.77
Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science (2002) 4.02
Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res (2012) 2.48
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res (2011) 2.44
Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials. Clin Trials (2010) 2.24
Patients with Merkel cell carcinoma tumors < or = 1.0 cm in diameter are unlikely to harbor regional lymph node metastasis. J Clin Oncol (2009) 1.94
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med (2008) 1.77
Impact of patient distance to radiation therapy on mastectomy use in early-stage breast cancer patients. J Clin Oncol (2005) 1.75
Sentinel node biopsy in vulvar and vaginal melanoma: presentation of six cases and a literature review. Ann Surg Oncol (2002) 1.50
Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials. Clin Trials (2011) 1.43
CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease. Cancer Res (2004) 1.43
Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. Cooperative Oncology Groups. Clin Cancer Res (2011) 1.42
Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling. J Biol Chem (2004) 1.39
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med (2009) 1.31
Shipping blood to a central laboratory in multicenter clinical trials: effect of ambient temperature on specimen temperature, and effects of temperature on mononuclear cell yield, viability and immunologic function. J Transl Med (2011) 1.31
A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer. J Immunother (2008) 1.25
Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma. J Immunol (2005) 1.23
Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin. J Transl Med (2005) 1.22
Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2. Cancer Res (2008) 1.16
Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis. J Cutan Pathol (2009) 1.12
Molecular insights on the peripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin) administration for the treatment of metastatic melanoma. Clin Cancer Res (2011) 1.10
Interferons induce CXCR3-cognate chemokine production by human metastatic melanoma. J Immunother (2010) 1.10
Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund's adjuvant, with or without peptide. Cancer Immunol Immunother (2013) 1.03
Comprehensive analysis of receptor tyrosine kinase activation in human melanomas reveals autocrine signaling through IGF-1R. Melanoma Res (2011) 1.03
Genomic organization, incidence, and localization of the SPAN-x family of cancer-testis antigens in melanoma tumors and cell lines. Clin Cancer Res (2004) 1.01
Use of selected reaction monitoring mass spectrometry for the detection of specific MHC class I peptide antigens on A3 supertype family members. Cancer Immunol Immunother (2004) 1.01
Surgical management of the patient with metastatic melanoma to the heart. J Card Surg (2013) 0.97
Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis. J Transl Med (2010) 0.97
MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma. Clin Cancer Res (2003) 0.96
The vaccine-site microenvironment induced by injection of incomplete Freund's adjuvant, with or without melanoma peptides. J Immunother (2012) 0.96
Subclassification of desmoplastic melanoma: pure and mixed variants have significantly different capacities for lymph node metastasis. J Cutan Pathol (2009) 0.95
Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2. J Immunother (2005) 0.95
Preventing the spontaneous modification of an HLA-A2-restricted peptide at an N-terminal glutamine or an internal cysteine residue enhances peptide antigenicity. J Immunother (2004) 0.94
Intraoperative imaging guidance for sentinel node biopsy in melanoma using a mobile gamma camera. Ann Surg (2011) 0.94
Amelanotic melanomas presenting as red skin lesions: a diagnostic challenge with potentially lethal consequences. Int J Dermatol (2012) 0.93
Problems in the interpretation of apparent "radial growth phase" malignant melanomas that metastasize. J Cutan Pathol (2002) 0.93
Defective human leukocyte antigen class I-associated antigen presentation caused by a novel beta2-microglobulin loss-of-function in melanoma cells. J Biol Chem (2006) 0.93
T cells in the human metastatic melanoma microenvironment express site-specific homing receptors and retention integrins. Int J Cancer (2014) 0.93
Immunotherapy for melanoma. Cancer Control (2002) 0.91
Multi-peptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapies. Vaccine (2009) 0.88
Apoptosis of CD4(+)CD25(high) T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2. Cancer Immunol Immunother (2008) 0.87
Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine. Cancer Immunol Immunother (2014) 0.86
Identification of novel and widely expressed cancer/testis gene isoforms that elicit spontaneous cytotoxic T-lymphocyte reactivity to melanoma. Cancer Res (2004) 0.85
Extensive neurocristic hamartoma with skeletal muscle involvement. J Cutan Pathol (2007) 0.85
Competition among peptides in melanoma vaccines for binding to MHC molecules. J Immunother (2004) 0.85
Evaluation of molecular markers of mesenchymal phenotype in melanoma. Melanoma Res (2010) 0.84
VEGFR-2 expression in human melanoma: revised assessment. Int J Cancer (2011) 0.83
Infrared thermography of cutaneous melanoma metastases. J Surg Res (2012) 0.83
MicroRNAs induced in melanoma treated with combination targeted therapy of Temsirolimus and Bevacizumab. J Transl Med (2013) 0.83
The use of gamma-irradiation and ultraviolet-irradiation in the preparation of human melanoma cells for use in autologous whole-cell vaccines. BMC Cancer (2008) 0.83
Outcome of sentinel lymph node biopsy and prognostic implications of regression in thin malignant melanoma. Melanoma Res (2012) 0.82
Neonatal congenital malignant melanoma with lymph node metastasis. J Clin Oncol (2009) 0.82
Melanoma NOS1 expression promotes dysfunctional IFN signaling. J Clin Invest (2014) 0.81
Identification of a shared epitope recognized by melanoma-specific, HLA-A3-restricted cytotoxic T lymphocytes. Immunol Lett (2003) 0.81
Skin mapping with punch biopsies for defining margins in melanoma: when you don't know how far to go. Ann Surg Oncol (2008) 0.80
Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma. J Clin Invest (2016) 0.80
The TAG family of cancer/testis antigens is widely expressed in a variety of malignancies and gives rise to HLA-A2-restricted epitopes. J Immunother (2008) 0.79
Assessment of the toxicities of systemic low-dose interleukin-2 administered in conjunction with a melanoma peptide vaccine. J Immunother (2004) 0.78
Research incentive program for clinical surgical faculty associated with increases in research productivity. J Thorac Cardiovasc Surg (2012) 0.78
Utility of sentinel lymph node biopsy for solitary dermal melanomas. J Surg Oncol (2015) 0.78
Interface of signal transduction inhibition and immunotherapy in melanoma. Cancer J (2010) 0.77
Two patients with Hailey-Hailey disease, multiple primary melanomas, and other cancers. Arch Dermatol (2011) 0.77
Immunolabeling for p16, WT1, and Fli-1 in the assignment of growth phase for cutaneous melanomas. Am J Dermatopathol (2014) 0.76
Surgical resection for bulky or recurrent axillary metastatic melanoma. J Surg Oncol (2011) 0.76
Lymphoscintigraphy and sentinel node biopsy accurately stage melanoma in patients presenting after wide local excision. Ann Surg Oncol (2003) 0.75
Design, development, and evaluation of a novel retraction device for gallbladder extraction during laparoscopic cholecystectomy. J Gastrointest Surg (2013) 0.75
Long-term outcomes of helper peptide vaccination for metastatic melanoma. Ann Surg (2015) 0.75
Inflammatory adverse events are associated with disease-free survival after vaccine therapy among patients with melanoma. Ann Surg Oncol (2014) 0.75
A triangular intermuscular space sentinel node in melanoma: association with axillary lymphatic drainage. Ann Surg Oncol (2010) 0.75
Short length of stay and rapid recovery to normal function after surgery for metastatic melanoma to abdominal and retroperitoneal viscera. J Surg Oncol (2009) 0.75
Usefulness of prestudy assessment of patient willingness to undergo tissue biopsy for correlative studies in a melanoma vaccine trial. Clin Trials (2012) 0.75
Resident research forums stimulate novel research within general surgical training programs. J Surg Educ (2009) 0.75
A case of spontaneous systemic immunity to melanoma associated with cure after amputation for extensive regional recurrence. Cancer Immunol Immunother (2013) 0.75
Regional control and morbidity after superficial groin dissection in melanoma. Ann Surg Oncol (2010) 0.75
Innovations and challenges in melanoma: summary statement from the first Cambridge conference. Clin Cancer Res (2006) 0.75
Histopathologic review of negative sentinel lymph node biopsies in thin melanomas: an argument for the routine use of immunohistochemistry. Melanoma Res (2017) 0.75
Methylene Blue for Vasoplegic Syndrome. Heart Surg Forum (2017) 0.75
Low-dose IL-2 induces cytokine cascade, eosinophilia, and a transient Th2 shift in melanoma patients. Cancer Immunol Immunother (2005) 0.75
The heterogeneity of tumor-infiltrating CD8+ T cells in metastatic melanoma distorts their quantification: how to manage heterogeneity? Melanoma Res (2017) 0.75